Protocol Ledger

NCT03635788 · Phase III · COMPLETED

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Interventional Phase III clinical trial protocol NCT03635788 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-28 Enrollment: 456 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03635788
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)456 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03635788
Protocol FieldVerified Registry Value
NCT IdentifierNCT03635788
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment456 participants (ACTUAL)
Registered Start Date2019-03-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI